Going Public Biotechnology Magazine p.76-77
The new upcoming GCP E6(R2) addendum reforms clinical monitoring and clinical trial management. Risk factors are an important component. What this means for a biotech company: clinical trial risks are easy to foresee, site level risks and operational risks are hard to detect; in this article, you will find a step by step approach to how to turn the new regulation to your best advantage.
By Artem Andrianov, PhD
See more in the article in Going Public Biotechnology magazine, p.76-77.
Leave A Comment
You must be logged in to post a comment.